Background

Since the emergence of CRISPR-Cas9 technology in academia and industry, disputes over core original patents have served as a decisive variable in defining the commercialization path of genome engineering over the past decade. The long-standing dispute between the Broad Institute and UC Berkeley has left excessive royalty burdens and licensing bottlenecks for technologies based on single nuclease enzymes.

To bypass these intellectual property (IP) risks and increase editing efficiency and target accuracy, academia and biotech companies have focused on developing new enzyme groups and editing platforms beyond Cas9. Second and third-generation gene tools, such as Base Editors (BE), Prime Editors (PE), and recently emerging large-scale sequence insertion technologies based on retrotransposons, are successively entering the patent offices. Consequently, identifying the latest patent trends has become a prerequisite for survival, rather than an option, for companies seeking to build commercial development pipelines.

Key Findings

Recently disclosed genome editing patent portfolios reflect a complex and diversified technological system. While existing Cas9-based technologies focused on modifications of natural nucleases derived from bacterial immune systems, recently registered and filed patents have shifted their center of gravity toward novel nucleases designed through AI-based protein engineering, fusion protein domains, and delivery vehicle complex compositions.

According to patent analysis data, there has been a surge in claims related to various subtypes of the Cas12 family (Cas12a, Cas12f, etc.) and small CRISPR enzymes (CasMINI, Cas12m, etc.). To overcome the packaging capacity limit of approximately 4.7 kilobases (kb) of adeno-associated virus (AAV) vectors, ultra-small gene editing compositions that reduce their size by more than 50% are becoming core claims.

Furthermore, a trend is emerging in which non-DNA double-strand break (DSB)-inducing modification technologies are establishing independent patent barriers. There are continuous filings for systems fusing deaminases and reverse transcriptases to Cas protein nickases, as well as the PASTE (Programmable Addition via Site-specific Targeting Elements) platform for large-scale sequence insertion and recombinase compositions based on Bridge RNA. Notably, there is a prominent increase in broad combination patents that encompass not just single enzymes, but also specific formulations of Lipid Nanoparticles (LNP), a non-viral delivery vehicle, and target cell-specific ligand binding technologies.

Implications and Outlook

The securing of rights for next-generation editing technologies is a result of learning from past litigation experiences. Latecomers are carefully delineating their claim scopes to defend exclusive rights without infringing on existing intellectual property. Research institutions and pharmaceutical companies are now facing structural pressure to design multi-layered patent portfolios rather than relying on a single source technology.

Conversely, in the clinical entry and commercialization stages, the complex patent licensing landscape is likely to act as a new barrier. This is because commercializing therapeutics for specific diseases will frequently require cross-licensing rights held by different entities, such as editing enzymes, guide RNA modification technologies, and delivery encapsulation formulations. The formation of patent pools and consortia is expected to be a major watershed that determines the speed of commercialization in the future biotech ecosystem.